期刊文献+

反相离子对高效液相色谱法检查盐酸伊立替康(CPT-11)有关物质

RP-HPLC determination of irinotecan hydrochloride(CPT-11) and its related substances
原文传递
导出
摘要 目的:采用反相离子对高效液相色谱法优化盐酸伊立替康中有关物质的检查方法。方法:采用C18色谱柱(150 mm×4.6 mm,5μm),以甲醇-20 mmol·L-1磷酸氢二钠溶液(含7.7 mmol·L-1辛烷磺酸钠)(50∶50)为流动相进行等度洗脱,检测波长为255 nm,柱温40℃。结果:经优化的反相离子对色谱法明显改善了盐酸伊立替康和各有关物质的保留行为及分离情况,色谱运行总时间不超过10 min。进一步通过强制降解试验验证了该色谱方法的专属性。结论:本方法简单快速,有利于满足伊立替康有关物质检查的质量控制要求。 Objective:To optimize the testing method of irinotecan hydrochloride and its related substances by re- versed - phase ion - pair high performance chromatography ( RP - HPLC). Methods: The optimized separation was operated on a ClS column( 150 mm ×4. 6 mm,5 μm)with an isocratie mobile phase composed of methanol- 20 mmol ·L - 1 disodium hydrogen phosphate ( containing 7.7 mmol · L- 1 octane sulfonate) ( 50: 50). The column temperature was set at 40 ℃ and the UV detection wavelength was 255 nm. Results: The RP - HPLC method sig- nificantly improved the retention behavior and separation of irinotecan hydrochloride and its related substances. The total operation time was no more than 10 min. Specificity was further assessed though the forced degradation tests. Conclusion:The optimized method is rapid and sensitive which is practical in accordance with the quality control requirement of testing the related substances in irinotecan hydrochloride
出处 《药物分析杂志》 CAS CSCD 北大核心 2013年第3期439-442,共4页 Chinese Journal of Pharmaceutical Analysis
基金 盐城师范学院教授基金(09YSYJB0204)
关键词 高效液相色谱 离子对 盐酸伊立替康 杂质分析 强制降解 质量控制 喜树碱衍生物 HPLC ion - pair irinotecan hydrochloride ( CFF - 11 ) impurity analysis forced degradation quality control camptothecin derivatives
作者简介 通讯作者Tel:(021)50806053;E—mail:dychen00@hotmail.com
  • 相关文献

参考文献15

  • 1Redinbo MR,Stewart L,Kuhn P,et al. Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA.Science,1998,279:1504.
  • 2Stewart L,Redinbo MR,Qiu X,et al. A Model for the mechanism of human topoisomerase I.Science,1998,279:1534.
  • 3Saltz LB,Cox JV,Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.Irinotecan study group.N Engl J Med,2000,343:905.
  • 4Douillard JY,Cunningham D,Roth AD,et al.Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer:a multicentre randomised trial.Lancet,2000,355:1041.
  • 5Rothenberg ML.Irinotecan (CPT-11):recent developments and future directions—colorectal cancer and beyond.Oncologist,2001,6:66.
  • 6方岩雄,熊绪杰,吕钱江,王亚莉,张焜.喜树碱衍生物的合成研究进展[J].合成化学,2003,11(2):119-123. 被引量:11
  • 7李玉艳,尤启冬,李志裕,王华.抗肿瘤新药伊立替康的合成研究[J].中国药物化学杂志,2001,11(4):238-240. 被引量:9
  • 8State Food and Drug Administration(国家食品药品监督管理局).National Drug Standards(国家药品标准).WS1-(X-339)-2003Z.
  • 9The United States Pharmacopeia Convention,Revision Bulletin,2010.
  • 10狄斌,冯芳,于立洁,宋华琳,张正行.抗癌新药伊立替康有关物质的研究[J].中国药科大学学报,1999,30(3):196-198. 被引量:3

二级参考文献11

共引文献70

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部